PurMinds NeuroPharma Chief Innovation Officer to Speak at Wonderland Conference

October 26, 2023 8:00 AM EDT | Source: Microdose Psychedelic Insights

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 26, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, today announced that Dr. Amy Reichelt, Ph.D., the company's Chief Innovation Officer, will be speaking at the 2023 Wonderland Conference, taking place November 9-11 in Miami.

Dr. Reichelt will be part of the "Designing the Future: Safer and Effective Psychoactive Compounds for Mental Health '' panel on November 10 at 12:00pm. She will discuss PurMinds' innovative approaches to developing new psychedelic-based treatments for neurological health diseases.

"I'm honored to join industry leaders in discussing the tremendous promise of psychedelic medicine to transform healthcare at this premier event," said Dr. Reichelt. "PurMinds is at the forefront of developing safe, effective new therapies, and I look forward to sharing our progress and vision."


PurMinds™ is a neurological drug development company pursuing breakthrough solutions to neurological and neurodegenerative disorders. Its clinical pipeline includes innovative therapeutics that combine proven mechanisms of action with the powerful ability of psychedelics and other psychoplastogens to rapidly promote neuroplasticity and neuro-rejuvenation, and its drug development program includes the potential for FDA "Breakthrough Designation" with a fast track to Phase IIa. The company's Ontario NeuroLab and Production Facility was granted a Schedule 1 Health Canada Controlled Drugs and Substances Dealer's License authorizing the production, formulation and global supply of pharma-grade Psychedelic compounds including Psilocybin and MDMA for clinical trials and research studies. PurMinds™ champions a de-risked business model that includes a multi-target approach to drug development, progressing long-term value creation through the accelerated development of novel therapeutics, accompanied by short and mid-term revenue paths. PurMinds™ is headquartered in Toronto, ON Canada with offices in Boston, MA USA. For further information about PurMinds™ NeuroPharma, please visit the Company's website at PurMinds.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to known and unknown risks, uncertainties and assumptions and accordingly, actual results and future events could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. All statements other than statements of present or historical fact are forward-looking statements, including statements with respect to PurMinds™' future business plans and partnerships. Forward-looking statements include words or expressions such as "proposed", "anticipated", "will", "subject to", "near future", "in the event", "would", "expect", "prepared to" and other similar words or expressions and include, but are not limited to: the ability of PurMinds™ to secure patent protection; the regulatory environment in which PurMinds™ operates; the ability of PurMinds™ to carry out its business plans and unforeseen challenges in carrying out such plans; trends in the future use of psychedelics; general business, economic, competitive, political and social uncertainties; the state of capital markets; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We disclaim any obligation to update or revise these forward-looking statements, except as required by applicable law.


Wonderland showcases medicine and therapies of the future - psychedelic medicine, longevity and mental health. The event is a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business. It acts as a launching pad for disruptive innovation related to the medicine and therapies of the future with musical showcases and documentary screenings, providing compelling entertainment and collaboration opportunities for attendees. Emphasizing the critical intersection of longevity, mental health, and psychedelic therapy, Wonderland is dedicated to delivering real-life events featuring high-quality programming at its stunning Miami location and venue.

Events Contact:

Kristina Spionjak



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/185242